It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal cancer patients with certain mutations, and the FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback